---
title: "Humacyte - CW27 | 10-Q: FY2025 Q2 Revenue: USD 301 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252554101.md"
datetime: "2025-08-11T21:03:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252554101.md)
  - [en](https://longbridge.com/en/news/252554101.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252554101.md)
generator: "portal-rs"
---

# Humacyte - CW27 | 10-Q: FY2025 Q2 Revenue: USD 301 K

Revenue: As of FY2025 Q2, the actual value is USD 301 K.

EPS: As of FY2025 Q2, the actual value is USD -0.24.

EBIT: As of FY2025 Q2, the actual value is USD -29.73 M.

### Segment Revenue

-   **Product Revenue, Net**: $0.1 million for the three months ended June 30, 2025, and $0.2 million for the six months ended June 30, 2025, from sales of Symvess in the United States.
-   **Contract Revenue**: $0.2 million for the three months ended June 30, 2025, and $0.6 million for the six months ended June 30, 2025, related to research and development services.

### Operational Metrics

-   **Net Income (Loss)**: Net loss of $37.7 million for the three months ended June 30, 2025, compared to a net loss of $56.7 million for the same period in 2024. Net income of $1.5 million for the six months ended June 30, 2025, compared to a net loss of $88.6 million for the same period in 2024.
-   **Research and Development Expenses**: $22.0 million for the three months ended June 30, 2025, a decrease from $23.8 million for the same period in 2024. $37.4 million for the six months ended June 30, 2025, a decrease from $45.0 million for the same period in 2024.
-   **Selling, General and Administrative Expenses**: $7.8 million for the three months ended June 30, 2025, an increase from $5.7 million for the same period in 2024. $15.9 million for the six months ended June 30, 2025, an increase from $11.1 million for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: $55.0 million for the six months ended June 30, 2025, compared to $48.6 million for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $48.9 million for the six months ended June 30, 2025, compared to $62.3 million for the same period in 2024.

### Unique Metrics

-   **Change in Fair Value of Contingent Earnout Liability**: Non-cash gain of $44.3 million for the six months ended June 30, 2025, compared to a non-cash loss of $30.2 million for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to commercialize Symvess in the U.S. for vascular trauma and, if approved, in AV access for hemodialysis. It also aims to obtain marketing approval for its 6 millimeter ATEV in additional indications and expand its manufacturing facility to meet potential market demand.
-   **Non-Core Business**: The company is exploring the application of its technology across a broad range of markets and indications, including the development of urinary conduit, trachea, esophagus, and other novel cell delivery systems.

### Related Stocks

- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [3,759 Shares in Ferrari N.V. $RACE Acquired by X Square Capital LLC](https://longbridge.com/en/news/296700358.md)
- [Powerful Growth, Multiple Endorsements Bode Well for Oracle Stock](https://longbridge.com/en/news/296686709.md)
- [Korea Investment CORP Increases Stock Position in L3Harris Technologies Inc $LHX](https://longbridge.com/en/news/296698330.md)
- [Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.](https://longbridge.com/en/news/296697035.md)
- [Danske Bank A S Invests $252.05 Million in Bank of America Corporation $BAC](https://longbridge.com/en/news/296695181.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**